NCT02146313.

Trial name or title	A phase I, open‐label, dose‐escalation study of the safety, tolerability, and pharmacokinetics of DMUC4064A administered intravenously to patients with platinum‐resistant ovarian cancer or unresectable pancreatic cancer
Methods	Non‐randomised phase I
Participants	30 participants with platinum‐resistant ovarian cancer or unresectable pancreatic cancer
Interventions	Intravenous DMUC4064A
Outcomes	DLT Adverse events Immune response Clinical response
Starting date	May 2014
Contact information
Notes	Active not recruiting, March 2018